Alnylam Pharmaceuticals Financials - Benzinga

Alnylam Pharmaceuticals Inc

ALNYNASDAQ

Trade with Public

Trade with Public

$255.36

-0.60-0.23%

al cierre: Sep 25, 5:00 PM EST

$255.36

-0.60-0.23%

Premercado: 8:16 AM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Alnylam Pharmaceuticals Financials

Alnylam Pharmaceuticals (ALNY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.

Vandana Singh

PRO
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est

Alnylam Pharmaceuticals (NASDAQ:ALNY) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.275 billion-$5.725 billion vs $5.580 billion estimate.

Benzinga Newsdesk

PRO
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.84 per share which beat the analyst consensus estimate of $1.55 by 18.71 percent. This is a 475 percent increase over earnings of $0.32 per share

Benzinga Newsdesk

PRO
Alnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.300B-$5.800B vs $5.545B Est

Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.300 billion-$5.800 billion vs $5.545 billion estimate.

Benzinga Newsdesk

PRO
Alnylam Pharmaceuticals Q1 Adj. EPS $1.99 Beats $0.93 Estimate, Sales $1.167B Beat $1.114B Estimate

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $0.93 by 113.98 percent. This is a 586.21 percent increase over earnings of $0.29 per

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved